Maravai Lifesciences Holdings (MRVI) Capital Expenditures Growth (3y) (2023 - 2026)

Maravai Lifesciences Holdings (MRVI) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Oculis Holding AG 69,146.49 Bn 69,146.20 Bn - -
2 Nanobiotix 1,942.19 Bn 1,942.13 Bn - -
3 Akari Therapeutics 1,132.35 Bn 1,132.35 Bn - -
4 BeOne Medicines 475.42 Bn 470.63 Bn 1.35 Bn -12.25%
5 Vertex Pharmaceuticals 123.32 Bn 116.08 Bn 2.59 Bn 46.88%
6 Regeneron Pharmaceuticals 69.80 Bn 61.04 Bn 3.31 Bn 8.97%
7 Belite Bio 63.28 Bn 63.28 Bn - -
8 Argenx Se 56.67 Bn 51.48 Bn 1.41 Bn -
9 Revolution Medicines 38.15 Bn 38.15 Bn - -
10 Maravai Lifesciences Holdings 1.01 Bn 844.42 Mn 33.70 Mn -17.38%

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.38%
Dec 31, 2025 49.38%
Sep 30, 2025 -46.00%
Jun 30, 2025 35.77%
Mar 31, 2025 -6.28%
Dec 31, 2024 -44.36%
Sep 30, 2024 1.73%
Jun 30, 2024 320.20%
Mar 31, 2024 38.04%
Dec 31, 2023 -93.83%
Sep 30, 2023 5.92%
Jun 30, 2023 433.74%
Mar 31, 2023 32.15%